{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021225","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.790612+00:00","generated_at":"2026-06-15T04:12:51.739004+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics Q1 2023 net loss $18.4M; cash $171M; BDC-1001 Phase 2 plans","bullets":["Net loss from operations $18.4M vs $23.9M in Q1 2022; collaboration revenue $1.8M (up from $0.8M).","Cash, equivalents, and marketable securities $171.0M as of March 31, 2023; expected to fund operations through 2025.","R&D expenses $14.6M (down from $18.4M) due to lower manufacturing and pipeline reprioritization.","BDC-1001 Phase 2 program to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer.","Comprehensive BDC-1001 safety/efficacy data to be presented at ASCO 2023 on June 3."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021225","json":"https://secwatch.observer/filing/0000950170-23-021225.json","markdown":"https://secwatch.observer/filing/0000950170-23-021225.md","text":"https://secwatch.observer/filing/0000950170-23-021225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017023021225/0000950170-23-021225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017023021225/bolt-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:12:51.739004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9cf6028cfd64719b98f1b710a02c1a4e28494ed","claim":"Bolt Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000095017023021225/0000950170-23-021225-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}